Degron Therapeutics Co-Founder Provides New Strategy for Molecular Glue in Tumor Immunotherapy

Research published in Cell Chemical Biology showed lenalidomide can enhance cancer-treating ability of PD-1 antibody SAN DIEGO and SHANGHAI, June 27, 2022 /PRNewswire/ — Degron Therapeutics (“Degron”), a biotechnology company developing a new class of small-molecule medicines that target…

Click here to view original post